CytoCore Announces Dr. Steven Waggoner Joins Company's Medical Advisory Board.CHICAGO -- CytoCore, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : MCDG.OB) today announced that Dr. Steven Waggoner will be joining the Company's Medical Advisory Board. Dr. Waggoner is Chief, Division of Gynecologic Oncology, at University Hospitals of Cleveland University Hospitals is a major not-for-profit medical center in Cleveland, Ohio, United States. With 150 locations throughout northeast Ohio, it encompasses a network of hospitals, outpatient centers and primary care physicians. ; Vice-Chairman of Clinical Affairs, Department of Obstetrics and Gynecology obstetrics and gynecology Medical and surgical specialty concerned with the management of pregnancy and childbirth and with the health of the female reproductive system. at MacDonald Women's Hospital; and Associate Professor at Case Western Reserve University School of Medicine. Dr. Waggoner has been recognized as one of the best physicians in his field, receiving a variety of "Top Doctor" and "Top Women's Doctor in America" citations. Dr. Waggoner is active in clinical research at University Hospitals and the Case Comprehensive Cancer Center. He has extensive experience in the design and conduct of human subject clinical trials, and holds leadership positions in the NCI See Liberate. sponsored Gynecologic Oncology Group The Gynecologic Oncology Group (GOG) is a non-profit organization funded by the National Cancer Institute with the purpose of supporting research for the prevention and treatment of all gynecologic cancers, such as ovarian cancer, cervical cancer, endometrial cancer, vulvar cancer, and the Society of Gynecologic Oncologists The Society of Gynecologic Oncologists (SGO), headquartered in Chicago, Illinois, is a national society of physicians trained in treating female reproductive cancers, especially gynecologic oncologists. . Dr. Waggoner serves as a peer reviewer for major publications in the field: Obstetrics and Gynecology, Gynecologic Oncology, Cancer, International Journal of Gynecological gynecological /gy·ne·co·log·i·cal/ (-kah-loj´i-k'l) gynecologic. Cancer, The Lancet, and Clinical Cancer Research. Dr. Waggoner will assist Dr. Gorodeski and the Company's research teams in the development, activation, conduct, and analysis of clinical trials designed to test the accuracy and practicality for the CVX/GCI Assay, the Endometrial Cancer Endometrial Cancer Definition Endometrial cancer develops when the cells that make up the inner lining of the uterus (the endometrium) become abnormal and grow uncontrollably. Screen, and the Drug Delivery Device. CytoCore's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Dr. David Weissberg stated: "We are very pleased to have Dr. Waggoner join our Medical Advisory Board. His distinguished medical career has been dedicated to addressing Gynecological Cancers. He has demonstrated consistent leadership in searching for new ways to address and stop this specific women's reproductive cancer. We believe Dr. Waggoner will be able to make a substantial contribution in defining and focusing the development and clinical trials for our bio-markers." Dr. George Gorodeski commented: "I am pleased with Dr. Waggoner joining the Medical Advisory Board. Dr. Waggoner is now recognized as a leading expert in the filed of GYN-ONC, and has demonstrated broad vision towards enhancing research and its application in fields that CytoCore is developing. Undoubtedly through his assistance CytoCore will be able to better focus its plans to meet the goals of developing cutting-edge biotechnology for early detection and prevention of gynecological dysplasia dysplasia Abnormal formation of a bodily structure or tissue, usually bone, that may occur in any part of the body. Several types are well-defined diseases in humans. and malignancies." About CytoCore Inc. CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial endometrial /en·do·me·tri·al/ (en?do-me´tre-il) pertaining to the endometrium. endometrial, n relating to the end-ometrium or cavity of the uterus. , and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer screening and treatment system that can be integrated into existing medical models or at the point-of-care. More information is available at: www.Molecular-Dx.com Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2004 and its Quarterly Reports on Form 10-QSB for the quarters ended June 30, 2005 and September 30, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion